Sinopharm Group Co Ltd
XBER:X2S
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Sinopharm Group Co Ltd
XBER:X2S
|
CN |
|
S
|
SGL Carbon SE
XBER:SGL
|
DE |
|
Blue Bird Tbk PT
IDX:BIRD
|
ID |
|
Renalytix PLC
LSE:RENX
|
UK |
|
McDonald's Corp
NYSE:MCD
|
US |
|
T
|
Telus International Cda Inc
NYSE:TIXT
|
CA |
|
Inter Cars SA
F:7FZ
|
PL |
|
A
|
Anheuser-Busch Inbev SA
XMUN:1NBA
|
BE |
Wall St Price Targets
X2S Price Targets Summary
Sinopharm Group Co Ltd
According to Wall Street analysts, the average 1-year price target for X2S is 3.174 EUR with a low forecast of 2.356 EUR and a high forecast of 3.885 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is X2S's stock price target?
Price Target
3.174
EUR
According to Wall Street analysts, the average 1-year price target for X2S is 3.174 EUR with a low forecast of 2.356 EUR and a high forecast of 3.885 EUR.
What is the Revenue forecast for Sinopharm Group Co Ltd?
Projected CAGR
5%
Over the last 14 years, the compound annual growth rate for Revenue has been 13%. The projected CAGR for the next 3 years is 5%.
What is the Gross Profit forecast for Sinopharm Group Co Ltd?
Projected CAGR
9%
Over the last 14 years, the compound annual growth rate for Gross Profit has been 12%. The projected CAGR for the next 3 years is 9%.
What is the Operating Income forecast for Sinopharm Group Co Ltd?
Projected CAGR
9%
Over the last 14 years, the compound annual growth rate for Operating Income has been 11%. The projected CAGR for the next 3 years is 9%.
What is the Pre-Tax Income forecast for Sinopharm Group Co Ltd?
Projected CAGR
10%
Over the last 14 years, the compound annual growth rate for Pre-Tax Income has been 12%. The projected CAGR for the next 3 years is 10%.
What is the Net Income forecast for Sinopharm Group Co Ltd?
Projected CAGR
10%
Over the last 14 years, the compound annual growth rate for Net Income has been 11%. The projected CAGR for the next 3 years is 10%.
